IPH 5401

Drug Profile

IPH 5401

Alternative Names: Anti-C5aR-215; NN-8210; NNC-0215-0384

Latest Information Update: 20 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Developer Innate Pharma; Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 02 Jun 2017 Preclinical trials in Cancer in France (unspecified route)
  • 02 Jun 2017 Innate Pharma acquires IPH 5401 from Novo Nordisk
  • 02 Jun 2017 Innate Pharma plans clinical trials for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top